dementia-2016_scientifictracks-abstracts

17 / 46

Notes:
Page 36
Dementia 2016
September 29-October 01, 2016
Volume 6 Issue 5(Suppl) J Alzheimers Dis Parkinsonism 2016
ISSN:2161-0460 JADP, an open access journal
conferenceseries .com
September 29-October 01, 2016 London, UK
5th International Conference on
Alzheimer’s Disease & Dementia
Xiao-lin Yu et al., J Alzheimers Dis Parkinsonism 2016, 6:5(Suppl)
AscFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses
Xiao-lin Yu, Jun Zha, Xiang-meng Liu, Jie Zhu, Shuai Lu, Peng-xin Xu and Rui-tian Liu
Chinese Academy of Sciences, China
Overproduction or poor clearance of amyloids lead to amyloid aggregation and even amyloidosis development. Different
amyloids may interact synergistically to promote their aggregation and accelerate pathology in amyloidoses. Amyloid
oligomers assembled from different amyloids share common structures and epitopes, and are considered the most toxic species
in the pathologic processes of amyloidoses, which suggests that an agent targeting the common epitope of toxic oligomers
could provide benefit to several amyloidoses. Here we firstly showed that an oligomer-specific single-chain variable fragment
antibody, W20 simultaneously attenuated motor and cognitive decline in Parkinson’s disease and Huntington’s disease
mouse models, and ameliorated neuropathology by reducing α-synuclein and mutant huntingtin protein aggregate load
and preventing synaptic degeneration. Neuroinflammation and oxidative stress in vivo were also markedly attenuated. The
proposed strategy targeting the common epitopes of amyloid oligomers presents promising potential for treating Parkinson’s
disease, Huntington’s disease, Alzheimer’s disease, and other amyloidoses.
Biography
Xiao-lin Yu has completed her PhD from Peking University Health Science Center and postdoctoral studies from National Institutes of Health, USA. She is an
associate professor of biotechnological drug engineering in Institute of Process Engineering. She has published more than 10 papers in reputed journals.